{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:24:52Z","timestamp":1793993092994,"version":"4.8.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect in cancer patients, yet studies have reported inconsistent incidence and influencing factors for CIPN. This study aims to systematically evaluate the incidence and influencing factors of CIPN in cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The search databases included PubMed, Embase, Cochrane Library, and Web of Science, focusing on CIPN incidence and influencing factors in cancer patients up to 10 June, 2025. A meta-analysis of incidence and influencing factors was performed separately by Stata 17.0 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      23 studies involving a sample size of 15,090 cases were included, and 16 influencing factors were identified. The incidence of CIPN in cancer patients was 56% (95% CI: 46\u201366%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.01). Age \u226550\u202fyears (\n                      <jats:italic>OR<\/jats:italic>\n                      \u202f=\u202f1.07, 95% CI: 1.03\u20131.10), BMI\u202f\u2265\u202f24\u202fkg\/m\n                      <jats:sup>2<\/jats:sup>\n                      (\n                      <jats:italic>OR<\/jats:italic>\n                      \u202f=\u202f1.15, 95% CI: 1.06\u20131.24), BMI\u202f\u2265\u202f30\u202fkg\/m\n                      <jats:sup>2<\/jats:sup>\n                      (\n                      <jats:italic>OR<\/jats:italic>\n                      \u202f=\u202f1.67, 95% CI: 1.43\u20131.95), anxiety or depression (\n                      <jats:italic>OR<\/jats:italic>\n                      \u202f=\u202f2.50, 95% CI: 1.20\u20135.20), hypertension (\n                      <jats:italic>OR<\/jats:italic>\n                      \u202f=\u202f1.98, 95% CI: 1.07\u20133.69), diabetes mellitus (\n                      <jats:italic>OR<\/jats:italic>\n                      \u202f=\u202f1.66, 95% CI: 1.29\u20132.13), cumulative dose of chemotherapy drugs (\n                      <jats:italic>OR<\/jats:italic>\n                      \u202f=\u202f2.52, 95% CI: 1.20\u20135.32), chemotherapy\u22654\u202fcycles (\n                      <jats:italic>OR<\/jats:italic>\n                      \u202f=\u202f1.21, 95% CI: 1.08\u20131.35), combination with taxane chemotherapy (per 10\u202fmg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) (\n                      <jats:italic>OR<\/jats:italic>\n                      \u202f=\u202f3.14, 95% CI: 1.81\u20135.44), vitamin D deficiency (\n                      <jats:italic>OR<\/jats:italic>\n                      \u202f=\u202f5.63, 95%CI: 2.64\u201311.99), high cholesterol (\n                      <jats:italic>OR<\/jats:italic>\n                      \u202f=\u202f1.34, 95% CI: 1.14\u20131.58), and transaminase elevation (\n                      <jats:italic>OR<\/jats:italic>\n                      \u202f=\u202f2.10, 95% CI: 1.55\u20132.84) were influencing factors for CIPN in cancer patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results show that the incidence of CIPN in cancer patients is at a high level, and its influencing factors are varied and complex. This suggests that clinicians should screen for CIPN early to improve clinical outcomes and enhance the quality of life and survival for cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:uri>\n                      , CRD420251010306.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1672180","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:18:55Z","timestamp":1771910335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Incidence and influencing factors of chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"He","family":"Yan","sequence":"first","affiliation":[{"name":"School of Nursing, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Dan","sequence":"additional","affiliation":[{"name":"School of Nursing, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Nana","sequence":"additional","affiliation":[{"name":"School of Nursing, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Dongqing","sequence":"additional","affiliation":[{"name":"School of Nursing, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Junming","sequence":"additional","affiliation":[{"name":"School of Nursing, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Xin","sequence":"additional","affiliation":[{"name":"Nursing Department, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/s1470-2045(19)30163-9","article-title":"Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study","volume":"20","author":"Wilson","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: a current review","volume":"81","author":"Staff","year":"2017","journal-title":"Ann Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/jco.20.01399","article-title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4149\/neo_2022_221007N992","article-title":"Prevention and therapy of chemotherapy-induced peripheral neuropathy: a review of recent findings","volume":"70","author":"Michalov\u00e1","year":"2023","journal-title":"Neoplasma"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.12998\/wjcc.v10.i10.3101","article-title":"Oxaliplatin-induced neuropathy and Colo-rectal cancer patient's quality of life: practical lessons from a prospective cross-sectional, real-world study","volume":"10","author":"Prutianu","year":"2022","journal-title":"World J Clin Cases"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11764-021-00988-x","article-title":"Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review","volume":"17","author":"Timmins","year":"2023","journal-title":"J Cancer Surviv"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"ref12","first-page":"1","article-title":"Celiac disease","volume":"104","author":"Rostom","year":"2004","journal-title":"Evid Rep Technol Assess"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"8151","DOI":"10.1002\/cam4.4328","article-title":"Chemotherapy-induced peripheral neuropathy in African American cancer survivors: risk factors and quality of life outcomes","volume":"10","author":"Trendowski","year":"2021","journal-title":"Cancer Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"978","DOI":"10.12968\/bjon.2023.32.20.978","article-title":"Living with chemotherapy-induced peripheral neuropathy: a nested qualitative study","volume":"32","author":"Mackereth","year":"2023","journal-title":"Br J Nurs"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jncc.2024.06.005","article-title":"Cancer survival statistics in China 2019-2021: a multicenter, population-based study","volume":"4","author":"Zeng","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"ref17","first-page":"226","article-title":"Diabetic peripheral neuropathy: prevention and treatment","volume":"109","author":"Bragg","year":"2024","journal-title":"Am Fam Physician"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/jco.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/j.pain.0000000000002320","article-title":"Antagonism of the mu-delta opioid receptor heterodimer enhances opioid antinociception by activating Src and calcium\/calmodulin-dependent protein kinase II signaling","volume":"163","author":"Keresztes","year":"2022","journal-title":"Pain"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3892\/ol.2025.15254","article-title":"Chemotherapy-induced peripheral neuropathy in patients with breast cancer treated with taxanes (review)","volume":"30","author":"Godiveau","year":"2025","journal-title":"Oncol Lett"},{"key":"ref22","first-page":"898","article-title":"The efficacy of acupuncture in the treatment of chemotherapy-induced peripheral neuropathy: a network meta-analysis","volume":"29","author":"Zhang","year":"2023","journal-title":"Altern Ther Health Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.3390\/cancers14051224","article-title":"Mechanisms, mediators, and moderators of the effects of exercise on chemotherapy-induced peripheral neuropathy","volume":"14","author":"Chung","year":"2022","journal-title":"Cancers"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00520-025-09145-x","article-title":"The effect of hand and foot exercises on peripheral neuropathy and quality of life in women with breast cancer: a randomized controlled trial","volume":"33","author":"Uysal","year":"2025","journal-title":"Support Care Cancer"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1200\/jco.2015.66.2346","article-title":"Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest Oncology group Clinical Trials","volume":"34","author":"Hershman","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1111\/tbj.14123","article-title":"Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer","volume":"26","author":"Pabst","year":"2020","journal-title":"Breast J"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jpainsymman.2019.04.029","article-title":"Deleterious effects of higher body mass index on subjective and objective measures of chemotherapy-induced peripheral neuropathy in Cancer survivors","volume":"58","author":"Petrovchich","year":"2019","journal-title":"J Pain Symptom Manag"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e13648","DOI":"10.1111\/ecc.13648","article-title":"Chemotherapy-induced peripheral neuropathy onset is associated with early risk of depression and anxiety in breast cancer survivors","volume":"31","author":"Mcneish","year":"2022","journal-title":"Eur J Cancer Care (Engl)"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/jcp.0000000000000442","article-title":"Modafinil moderates the relationship between Cancer-related fatigue and depression in 541 patients receiving chemotherapy","volume":"36","author":"Conley","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e13174","DOI":"10.1111\/eci.13174","article-title":"Heart rate variability in atrial fibrillation: the balance between sympathetic and parasympathetic nervous system","volume":"49","author":"Khan","year":"2019","journal-title":"Eur J Clin Investig"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2147\/dmso.S261175","article-title":"Effectiveness of exercise therapy on gait function in diabetic peripheral neuropathy patients: a systematic review of randomized controlled Trials","volume":"13","author":"Melese","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejon.2018.09.003","article-title":"Living with chemotherapy-induced peripheral neuropathy: uncovering the symptom experience and self-management of neuropathic symptoms among cancer survivors","volume":"36","author":"Chan","year":"2018","journal-title":"Eur J Oncol Nurs"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"472","DOI":"10.31925\/farmacia.2019.3.14","article-title":"Incidence of chemotherapy-induced peripheral neuropathy in cancer patients in clinical practice","volume":"67","author":"Mazilu","year":"2019","journal-title":"Farmacia"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e13832","DOI":"10.1111\/acel.13832","article-title":"Accelerated cerebromicrovascular senescence contributes to cognitive decline in a mouse model of paclitaxel (Taxol)-induced chemobrain","volume":"22","author":"Ahire","year":"2023","journal-title":"Aging Cell"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.neuroscience.2016.06.050","article-title":"Oxidative stress in the development, maintenance and resolution of paclitaxel-induced painful neuropathy","volume":"333","author":"Duggett","year":"2016","journal-title":"Neuroscience"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1096\/fj.15-272567","article-title":"Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathy","volume":"29","author":"Kramer","year":"2015","journal-title":"FASEB J"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of chemotherapy-induced peripheral neuropathy","volume":"20","author":"Zaj\u0105czkowska","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s10549-020-05584-8","article-title":"Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy","volume":"180","author":"Jennaro","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1002\/ptr.7984","article-title":"Honokiol attenuates high glucose-induced peripheral neuropathy via inhibiting ferroptosis and activating AMPK\/SIRT1\/PGC-1\u03b1 pathway in Schwann cells","volume":"37","author":"Hu","year":"2023","journal-title":"Phytother Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1327318","DOI":"10.3389\/fonc.2024.1327318","article-title":"Risk factors of paclitaxel-induced peripheral neuropathy in patients with breast cancer: a prospective cohort study","volume":"14","author":"Sun","year":"2024","journal-title":"Front Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/09603123.2022.2159016","article-title":"The role of thioredoxin and glutathione systems in arsenic-induced liver injury in rats under glutathione depletion","volume":"34","author":"Li","year":"2024","journal-title":"Int J Environ Health Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/ajco.13923","article-title":"Risk factors for taxane-induced peripheral neuropathy in patients with breast cancer","volume":"20","author":"Liang","year":"2024","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1080\/14796694.2024.2375959","article-title":"Prevalence and predictors for cisplatin-induced toxicities in Zimbabwean women with cervical cancer","volume":"20","author":"Kuguyo","year":"2024","journal-title":"Future Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e0261473","DOI":"10.1371\/journal.pone.0307865","article-title":"Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: a retrospective study in Japan","volume":"16","author":"Hiramoto","year":"2024","journal-title":"PLoS One"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1420518","DOI":"10.3389\/fonc.2024.1420518","article-title":"Chemotherapy-induced peripheral neuropathy and its determinants among adult cancer patients on chemotherapy in Northwest Ethiopia oncology centers, 2022","volume":"14","author":"Habtie","year":"2024","journal-title":"Front Oncol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/oncolo\/oyad062","article-title":"Patient characteristics associated with chemotherapyinduced peripheral neuropathy severity in a phase II clinical trial: a retrospective analysis","volume":"28","author":"Zhi","year":"2023","journal-title":"Oncologist"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10552-023-01676-0","article-title":"Chemotherapy-induced peripheral neuropathy in the Detroit research on cancer survivors (ROCS) cohort","volume":"34","author":"Sreeram","year":"2023","journal-title":"Cancer Causes Control"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/cancers15030754","article-title":"Correlates of taxane-induced neuropathy, an electronic health record based observational study","volume":"15","author":"Dorand","year":"2023","journal-title":"Cancers"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11764-021-01012-y","article-title":"The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors","volume":"16","author":"Timmins","year":"2022","journal-title":"J Cancer Surviv"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12032-022-01754-4","article-title":"Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: post hoc analysis of a prospective, phase II, self-controlled clinical trial","volume":"39","author":"Kanbayashi","year":"2022","journal-title":"Med Oncol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1159\/000524868","article-title":"Risk factors for nab-paclitaxel and gemcitabine-induced peripheral neuropathy in patients with pancreatic cancer","volume":"100","author":"Catalano","year":"2022","journal-title":"Oncology"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e2036695","DOI":"10.1001\/jamanetworkopen.2020.36695","article-title":"Hemoglobin, body mass index, and age as risk factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy","volume":"4","author":"Mizrahi","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"6666","DOI":"10.1002\/cam4.4202","article-title":"Prevalence and predictors of peripheral neuropathy after breast cancer treatment","volume":"10","author":"Kamgar","year":"2021","journal-title":"Cancer Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"12335","DOI":"10.21037\/apm-21-3313","article-title":"Glutathione combined with mecobalamin in the treatment of chemotherapy-induced peripheral neuropathy in multiple myeloma: a retrospective clinical study","volume":"10","author":"Huang","year":"2021","journal-title":"Ann Palliat Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12282-018-0919-8","article-title":"Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study","volume":"26","author":"Tsurutani","year":"2019","journal-title":"Breast Cancer"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e01312","DOI":"10.1002\/brb3.1312","article-title":"Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy","volume":"9","author":"Molassiotis","year":"2019","journal-title":"Brain Behav"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"P2.4-012","DOI":"10.1212\/WNL.92.15_supplement.P2.4-012","article-title":"The prevalence, severity and risk factors for chemotherapy induced peripheral neuropathy at 0 and 2 years after the completion of paclitaxel therapy (P2.4-012)","volume":"92","author":"Kolb","year":"2019","journal-title":"Neurology"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jpsychores.2018.02.012","article-title":"Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer","volume":"108","author":"Lee","year":"2018","journal-title":"J Psychosom Res"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"djx162","DOI":"10.1093\/jnci\/djx162","article-title":"Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG Oncology\/NSABP B-30","volume":"110","author":"Bandos","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10549-016-3939-0","article-title":"Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk","volume":"159","author":"Bao","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/CAD.0b013e32833db89d","article-title":"Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis","volume":"21","author":"Kanbayashi","year":"2010","journal-title":"Anti-Cancer Drugs"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1672180\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:18:57Z","timestamp":1771910337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1672180\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":61,"alternative-id":["10.3389\/fneur.2026.1672180"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1672180","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"article-number":"1672180"}}